We read with interest the debate on the treatment of carotid artery disease by Paraskevas et al. 1 This is indeed very controversial, and the optimal management of patients with asymptomatic carotid stenosis (ACS) or symptomatic carotid stenosis (SCS) needs to be elucidated in future randomized clinical trials (RCTs).
We discuss the results of 3 relevant RCTs published following the article by Paraskevas et al. 1 The first is the report of the long-term results of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) trial. 2, 3 Once again, the rate of the primary long-term end point (postprocedural ipsilateral stroke over the 10-year follow-up) did not differ significantly between the 2 groups (hazard ratio 0.99; 95% confidence interval [CI]: 0.64-1.52). However, CREST included both symptomatic and asymptomatic patients, and, more importantly, it did not compare carotid artery stenting (CAS) versus carotid endarterectomy (CEA) versus best medical treatment (BMT) for asymptomatic patients. As discussed by Paraskevas et al, 1 this comparison is urgently needed and it is the very reason why CREST-2 was launched.
A new RCT 4 evaluated the efficacy of CAS in patients with ACS having severe stenosis and low or moderate morbidity risk. CAS was not inferior to CEA in terms of stroke, death, or myocardial infarction (MI) within the first 30 days after intervention (3.3% vs 2.6%, P ¼ .6). Similarly, at 5-year follow-up, the survival rate for the CAS group was 87.1% and 89.4% for the CEA group (P ¼ .21), and the rate of freedom from nonprocedure-related ipsilateral stroke was 97.8% and 97.3%, respectively (P ¼ .51). Once again, this major RCT verified that CAS is associated with outcomes similar to CEA in patients with ACS. This, however, was already well known. The real issue (which is the comparison of CAS vs CEA vs BMT) was once again not addressed.
The outcomes of CEA under regional anesthesia (RA) is another issue that deserves to be explored. Another analysis of the CREST data 5 comparing CAS versus CEA under general anesthesia (GA) versus CEA-RA in both patients with SCS and patients with ACS demonstrated a noninferiority of CAS compared to CEA-RA in terms of periprocedural MI rates (odds ratio [OR]: 1.07; 95% CI: 0.25-4.66; P ¼ .93) and a superiority when compared to CEA-GA (OR: 2.01; 95% CI: 1.14-3.54; P ¼ .02). In terms of stroke or death, CAS was also not inferior compared to CEA-RA (OR: 0.20; 95% CI: 0.03-1.47; P ¼ .11) and inferior to CEA-GA (OR: 0.46; 95% CI: 0.27-0.76; P ¼ .003). In both groups, the percentage and number of patients with SCS and ACS were similar. The CEA-RA group included less patients with SCS compared to the other groups, so the correlation of CEA-RA and periprocedural stroke rates in patients with SCS should be cautiously evaluated and further elucidated.
Paraskevas et al 1 identify a number of issues that need to be addressed in future RCTs. The recent trials do not provide definitive answers. These issues must be specifically identified and addressed in well-planned, appropriately designed RCTs.
